Abdelhakim Ahmed-Belkacem, Alexandre Pozza, Sira Macalou, José M Pérez-Victoria, Ahcéne Boumendjel, Attilio Di Pietro
Institut de Biologie et Chimie des Protéines, UMR 5086 CNRS/Université de Lyon, IFR128 BioSciences Lyon-Gerland, Lyon, France.
Anti-cancer drugs 2006 MarBreast cancer resistance protein (BCRP/ABCG2) belongs to the ATP-binding cassette (ABC) transporter superfamily. It is able to efflux a broad range of anti-cancer drugs through the cellular membrane, thus limiting their anti-proliferative effects. Due to its relatively recent discovery in 1998, and in contrast to the other ABC transporters P-glycoprotein (MDR1/ABCB1) and multidrug resistance-associated protein (MRP1/ABCC1), only a few BCRP inhibitors have been reported. This review summarizes the known classes of inhibitors that are either specific for BCRP or also inhibit the other multidrug resistance ABC transporters. Information is presented on structure-activity relationship aspects and how modulators may interact with BCRP.
Abdelhakim Ahmed-Belkacem, Alexandre Pozza, Sira Macalou, José M Pérez-Victoria, Ahcéne Boumendjel, Attilio Di Pietro. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anti-cancer drugs. 2006 Mar;17(3):239-43
PMID: 16520651
View Full Text